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TransplantatABSTRACT
Introduction. Thrombotic microangiopathy (TMA) is characterized by endothelial cell
injury and formation of ﬁbrin thrombi within capillary and arterioles. In renal allograft
recipients, TMA mainly presents as hemolytic uremic syndrome. Its occurrence is rare, and
diagnosis requires a high degree of suspicion. Drug toxicity, in particular from calcineurin
inhibitors (CNIs) and mTOR inhibitors (mTORi), is the most common cause posttrans-
plant and has recently been emphasized in the setting of lung transplantation.
Objective. The goal of this study was to investigate the role of mTORi as an added risk
factor in the development of TMA to propose strategies for modulation of immunosup-
pressive (IS) therapy.
Patients and Methods. From a database of 496 renal graft recipients, we analyzed 350 renal
graft biopsy specimens gathered at our center from 1998 to 2012. In patients undergoing
combined therapy with mTORi and CNI, we compared drugs levels in TMA-affected and
TMA-free groups, using mTORi and CNI TLC and the summation of [everolimus TLC þ
(cyclosporine C2/100)] (S) as a surrogate marker of combined exposition to 2 drugs.
Receiver-operating characteristic analysis of association of EVL TLC þ (C2/100) was
performed for patients exposed to mTORi.
Results. Histologic features of TMA were found in 36 patients (prevalence of 7.3%). The
caseload was divided into 2 groups: not drug-related TMA (n ¼ 19) and drug-related TMA
(n ¼ 17). Despite the prevalence of TMA in patients exposed to mTORi being greater (8 of
153; prevalence, 5.3%) compared with therapies without mTORi (9 of 324; prevalence,
2.8%), statistical difference was not reached. Patients treated with mTORi who
developed de novo drug-related TMA had higher blood levels of IS drugs compared
with those who did not develop TMA. Receiver-operating characteristic analysis found a
signiﬁcant threshold of 12.5 ng/mL (area under the curve, 0.803; P ¼ .006).
Conclusions. Results conﬁrm the pivotal role of IS drugs in the onset of de novo TMA.On
the basis of literature, we could speculate a sequence of endothelial damage byCNI, onwhich
everolimus ﬁts hindering the repair of endothelial injury. Therefore, high blood levels of CNI
and mTORi seem to predispose patients to posttransplant TMA. Combined monitoring of
these 2 drugs might be used to prevent the complication. S [everolimus TLCþ (cyclosporine
C2/100)] >12.5 ng/mL should be avoided as a surrogate risk factor for adverse effects.*Address correspondence to Dr. Fabio Nava (MD, resident)
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lytic uremic syndrome (HUS) and thrombotic thrombocy-
topenic purpura; although HUS is distinguished by the
presence of more severe and refractory renal involvement,
thrombotic thrombocytopenic purpura has a typical neuro-
logic involvement and depends on ADAMTS13 dysfunction.
In renal allograft recipients, HUS is rare, with an inci-
dence ranging between 0.8% and 14% [1]. When unrecog-
nized and not treated early, it can lead to graft loss and, in
severe cases, death. Toxicity by calcineurin inhibitors (CNIs)
and mTOR inhibitors (mTORi), viral infection, ischemia-
reperfusion injury, antibody-mediated rejection (AMR),
and presence of antiphospholipid antibodies [2] are the
most frequent etiologies. Drug toxicity, in particular from
CNIs, is the most common cause of posttransplant HUS;
TMA has been a well-known adverse effect of cyclosporine
(CsA) since its ﬁrst use in transplantation [3]. Systemic signs
of CsA-related TMA are uncommon, underscoring the
importance of a graft biopsy for diagnosis. Conversely,
mTORi sirolimus (SIR) and everolimus (EVE) inhibit
glomerular endothelial cell proliferation and vascular
endothelial growth factor activity in experimental TMA
[4,5]. This could delay the repair of endothelial injury
caused by CNI cytotoxicity as a ﬁrst step in posttransplant
TMA pathogenesis. A recent study on lung transplantation
found that EVE and CsA association induced a high risk of
TMA/HUS (related to the drugs’ plasma levels) [6].
We retrospectively analyzed our transplant caseload with
3 main objectives: (1) to estimate the prevalence of biopsy-
proven TMA in our renal transplant patients; (2) to eval-
uate the role of immunosuppressive (IS) combinations and
their levels in the onset of TMA, with particular focus on
mTORi; and (3) to determine a surrogate indicator of
toxicity by IS combinations (CsA minimization and EVE).MATERIALS AND METHODS
We analyzed 350 renal graft biopsy specimens gathered from 1998 to
2012 in 496 renal graft recipients (excluding kidney/pancreas, kidney/
liver allografts, and primary nonfunction). Patients provided written
informed consent before graft biopsy; the biopsy was indicated on
clinical grounds (worsening renal function and/or proteinuria, signs
of hemolitic anemia such as lactate dehydrogenase elevation,
without other explanation). No protocol biopsies were performed.
In each patient with biopsy-proven TMA, we evaluated therapy
at the time of biopsy and time from transplantation at the onset,
interventions, and outcome expressed as graft loss. The cases were
divided into 2 groups: not drug-related TMA and drug-related
TMA. In the ﬁrst group, TMA was related to various clinical
pathologic conditions; for example, AMR, viral infections, systemic
lupus erythematosus, and recurrence of atypical HUS. In the second
group, TMA was linked exclusively to IS drugs.
Mean IS drug levels were measured in patients exposed to
mTORi comparing TMA and TMA-free groups. To ensure the
evaluation of a stabilized IS therapy, for the ﬁrst group we
considered the 3 months before biopsy, taking into account peak
values before the procedure.
For the latter (TMA-free as control subjects), we analyzed TLCs
for 6 months, after a minimum of 6 months of stabilized mTORitherapy. For statistical comparisons between patients with TMA
who were exposed or not exposed to mTORi, and between drug-
related and not drug-related TMA groups, a c2 analysis with
Yates’ correction was used. Drug blood levels were compared by
using the Student unpaired t test or nonparametric Mann-Whitney
U test where appropriate. SPSS (IBM SPSS Statistics 21.0, IBM
Corporation, Armonk, NY, United States) was used for statistical
analysis, and P < .05 was considered statistically signiﬁcant. Data
are presented as medians with ranges. Receiver-operating charac-
teristic analysis of the association of EVL TLC þ (C2/100) was
performed for patients exposed to mTORi.RESULTS
Thirty-six cases of TMA were found in 350 renal biopsy
specimens in a population of 496 patients receiving a renal
allograft. Prevalence was 7.3% (36 of 496). TMA that was
not drug related (n ¼ 19) included AMR (n ¼ 11), viral
infection (cytomegalovirus, human immunodeﬁciency virus)
(n ¼ 5), vasculitis (n ¼ 1), systemic lupus erythematosus
(n ¼ 1), and recurrent atypical HUS (n ¼ 1); drug-related
TMA was found in 3.4% of patients (n ¼ 17). Statistical
analysis found no signiﬁcant differences between the 2
groups (drug related and not drug related TMA), except for
distribution of histopathologic features of rejection, result-
ing prevalent in not drug related group (Tables 1 and 2).
The present study focused on the 17 patients of the drug-
related TMA group to investigate the speciﬁc role of IS
drugs. Drug-related TMA group prevalence was 3.4% (17 of
496). Patients with drug-related TMA did not differ signif-
icantly with respect to age (52  12 years) and sex (9 male
subjects, 8 female subjects). The allografts were single grafts
from a cadaveric donor in 14 of 17 cases. In 2 cases, it was a
double renal transplant; only 1 was from a living related
donor. The mean time between transplantation and onset of
de novo TMA was 276 days (range, 9 days to 4 years).
Eight cases of TMA were found in the mTORi-treated
group (n ¼ 153; prevalence, 5.3%); 6 were associated with
CsA-EVE and 2 with FK-EVE. Nine cases of TMA were
observed in patients not receiving mTORi (n ¼ 324), with a
prevalence of 2.8%; of these, 8 were treated with FK506 and
1 with CsA. A c2 analysis with Yates’ correction yielded no
signiﬁcant difference in the prevalence of TMA between the
2 groups (P ¼ .28). There were no cases of TMA in our
patients treated with SIR.
Patients treated with mTORi who developed de novo drug-
related TMA had higher blood levels of IS drugs compared
with thosewhodid not developTMA. In particular, serumCsA
TLC (C0) was 134.8  108.1 ng/mL in patients with TMA (6
cases) and 53.6 23.6 ng/mL in patients without TMA treated
with CsA (P < .05). C2 levels were statistically nonsigniﬁcant,
despite higher values in cases with TMA (588.8 433.2 ng/mL
vs 317.0  95.5 ng/mL; P ¼ .095). EVE TLC mean values,
when used in association with CsA, were 9.9  3.9 ng/mL in
patients with TMA and 7.5  2.2 ng/mL in patients without
TMA (P ¼ .0381). Noteworthy was the difference (P ¼ .034)
between the summation of concentrations of the 2 drugs: S
[EVE TLC þ (C2/100)]: 15.2  6.3 ng/mL in patients with
Table 1. Renal Graft Recipients With Drug-Related TMA
Patient Sex Age (y)
Native Renal
Disease Allograft
TMA Onset
Posttransplant (d) Prebiopsy Therapy CMV HIV HR DSA C4d LDH Blood Smear
1 M 35 Alport Living 128 FK þ EVE Neg Neg Neg e e ¼ e
2 F 45 Pyeloneph Single 253 CsA þ EVE Neg Neg Neg Neg Neg [ Neg
3 M 39 VUR Single 1494 CsA þ EVE Neg Neg Neg Neg Neg ¼ Neg
4 M 44 IgAN Single 138 CsA þ EVE Neg Neg Neg Neg Pos [ Neg
5 F 66 Lithiasis Double 343 CsA þ EVE Neg Neg Neg I Pos [ Neg
6 F 60 Interstitial Single 109 FK þ EVE Neg Neg Neg Neg Neg [ Neg
7 F 61 DN Single 33 CsA þ EVE Neg Neg Neg e Neg [ Hemolysis
8 M 64 DN Single 254 CsA þ EVE Neg Neg Neg II e [ e
9 M 54 Extracapillary GN Single 12 FK Neg Neg Neg I Neg ¼ Hemolysis
10 M 58 DN Single 558 FK Neg Neg Neg Neg Neg [ e
11 M 52 Mesangial GN Single 85 CsA Neg Neg Neg Neg Neg [ e
12 M 36 Focal GN Single na FK Neg Neg Neg e e e e
13 F 40 Focal GN Single 17 FK Neg Neg Neg e e e Hemolysis
14 F 40 ESRD Single 9 FK Neg Neg Neg e e [ Neg
15 M 71 Hypertensive Single 27 FK Neg Neg Neg Neg Neg [ Hemolysis
16 F 62 MPGN Double 336 FK Neg Neg Neg Neg Neg [ Hemolysis
17 F 43 GIN Single 626 FK Neg Neg Neg II Neg ¼ e
TOT Male Mean  SD S/D Mean  SD mTORi Pos Pos Pos DSAII Pos [LDH Hemolysis
17 9 51  12 15/2 276  377 8 0 0 0* 2 2 11 5
Abbreviations: CMV, cytomegalovirus; CsA, cyclosporine; DSA, donor-speciﬁc antibody; ESRD, end-stage renal disease; EVE, everolimus; F, female; GIN, granulomatous interstitial nephritis; HIV, human immuno-
deﬁciency virus; HR, histology compatible with rejection; LDH, lactate dehydrogenase; M, male; MPGN, membranoproliferative glomerulonephritis; Neg, negative; Pos, positive; SLE, systemic lupus erythematosus; TMA,
thrombotic microangiopathy; VUR, vesicoureteral reﬂux.
*Considered elevated if >400 UI/L.
P < .05 between drug-related and not drug-related groups.
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Table 2. Renal Graft Recipients With TMA That Is Not Drug Related
Patient Sex Age (y)
Native Renal
Disease Allograft
TMA Onset
Posttransplant (d) Prebiopsy Therapy CMV HIV HR DSA C4d LDH Blood Smear
1 F 59 ESRD Single 19 CsA Neg Neg Pos e e e e
2 M 39 ESRD Single 187 CsA Neg Neg Pos e e e Neg
3 M 51 HIVAN Single 23 CsA Neg Pos Neg Neg Neg e Hemolysis
4 F 56 ESRD Single 10 FK Neg Neg Pos I þ II Pos [ Hemolysis
5 M 52 ESRD Single 969 CsA Neg Neg Pos e e e Hemolysis
6 M 34 ESRD in HCVþ Single 8 CsA Neg Neg Pos I Pos e Hemolysis
7 M 62 GN Single 2569 CsA Neg Neg Pos I Pos ¼ e
8 M 32 VUR Single 115 FK Neg Neg Pos Neg e e e
9 M 77 Hypertensive Single 2768 CsA Neg Neg Pos e e ¼ e
10 M 40 IgAN Single 2962 CsA Neg Neg Neg I þ II Pos ¼ Hemolysis
11 M 54 Extracapillary GN Living 2463 FK Neg Neg Pos Neg Neg ¼ e
12 M 60 V-U reﬂux Single 11 Thymogl. Neg Neg Pos e e e e
13 M 48 HIVAN Single 3 EVE Neg Pos Neg Neg Neg ¼ Hemolysis
14 M 71 ESRD Double 15 EVE Pos Neg Neg Neg Neg ¼ Hemolysis
15 F 52 Atypical HUS Single 144 Sir Neg Neg Neg e Neg e e
16 M 50 Focal GN Single 199 FK Pos Neg Neg e e e Neg
17 M 37 SLE Single 3178 CsA Neg Neg Neg I Pos ¼ e
18 M 50 DN, HIVAN Single 653 CsA þ EVE Neg Pos Neg Neg Neg e e
19 M 65 Cryo GN Single 10 MMF Neg Neg Pos Neg Neg [ Neg
Total Male Mean  SD S/D Mean  SD mTORi (EVE/Sir) Pos Pos Pos DSAII Pos [LDH* Hemolysis
19 16 52  12 18/1 858  1217 4 (3/1) 2 3 11† 2 5 2 7
Abbreviations: CMV, cytomegalovirus; CsA, cyclosporine; DSA, donor-speciﬁc antibody; ESRD, end-stage renal disease; EVE, everolimus; F, female; GIN, granulomatous interstitial nephritis; HIV, human immuno-
deﬁciency virus; HR, histology compatible with rejection; LDH, lactate dehydrogenase; M, male; MPGN, membranoproliferative glomerulonephritis; Neg, negative; Pos, positive; SLE, systemic lupus erythematosus; TMA,
thrombotic microangiopathy; VUR, vesicoureteral reﬂux.
*Considered elevated if >400 UI/L.
†P < .05 between drug-related and not drug-related groups.
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Fig 2. Receiver-operating characteristic curve of association of
everolimus TLC þ (C2/100) (P) in patients exposed to mTOR in-
hibitors. Area under the curve, 0.803; P ¼ .006.
EVEROLIMUS, CYCLOSPORINE, AND TMA IN RENAL TRANSPLANTS 2267TMA and 10.7 2.1 ng/mL in patients without TMA (Fig 1).
Receiver-operating characteristic analysis found a signiﬁcant
threshold of 12.5 ng/mL (area under the curve, 0.803; P ¼
.006) (Fig 2). Tacrolimus (FK) TLC mean blood levels were
7.2 1.3 ng/mL in patients with TMA and 4.7 0.8 ng/mL in
patients without TMA (P ¼ .0075). Similarly, EVE TLC in
these patients was 15.3  8.1 ng/mL in patients with TMA
and 4.9  0.9 ng/mL in patients without TMA (P ¼ .0011).
EVE TLCþ FK TLC was 21.1 11.3 ng/mL in patients with
TMA and 9.6  1.3 ng/mL in patients without TMA.
DISCUSSION
The goal of this study was to investigate the role of IS drugs
in posttransplant TMA. We selected a TMA population not
inﬂuenced by classical risk factors (eg, AMR, viral in-
fections, vasculitides, systemic lupus erythematosus, recur-
rence of atypical HUS), in whom the role of the
antirejection medication appeared predominant. However,
we could not exclude the possible presence of underlying
causes unknown at the time of onset.
According to the literature, drug-induced HUS repre-
sents 13% of all HUS cases [7]. The real incidence of drug-
related TMA in renal graft recipients is not known; renal
biopsy is the only available method for diagnosis of TMA,
and indications for renal biopsy vary among medical centers.
The overall prevalence of TMA observed in our center since
1998 is 7.3%, which is in line with the reported series in
several studies [7e9].Fig 1. Summation of blood levels of everolimus TLC þ (C2/100)
in patients with drug-related thrombotic microangiopathy (TMA)
treated with the combination of cyclosporine (CsA) and everoli-
mus. Black diamonds represent S blood levels in patients with
TMA; grey diamonds represent S blood levels in graft recipients
without TMA. Vertical axis indicates blood concentration of drug
expressed in nanograms per milliliter. The number of patients
examined for each group is indicted in brackets. The line repre-
sents the S safety threshold of 12.5 ng/mL [everolimus TLC þ
(C2/100)] suggested by the receiver-operating characteristic
analysis.The association between TMA and CsA is well estab-
lished [10]. Although the prevalence of TMA in patients
exposed to mTORi in our study was greater (5.3% vs 2.8%
in patients exposed to CNI only), these differences were not
statistically signiﬁcant. The data regarding exposure to IS
could provide an explanation of this difference. Analyzing
blood levels of drugs in relation to the presence of TMA, we
found signiﬁcantly higher drug blood levels in patients with
TMA. Apart from the well-known relationship with CsA
basal levels, the values of the S are noteworthy; they
reached an average of 15.2 ng/mL in patients with TMA,
and in patients without TMA, the average summation was
10.7 ng/mL (P < .05).
Combined monitoring of IS drugs has recently proved to
be a useful tool for reducing the risk of rejection within the
ﬁrst months after transplant [11]. The results of the present
study support the use of combined monitoring to also pre-
dict and prevent the onset of de novo HUS. In fact, TMA in
renal allograft recipients treated with mTORi is very infre-
quent below speciﬁc values 12.5 ng/mL of S (Fig 1). Toxic
effects of CNI and mTORi interact in a synergistic way. We
hypothesize that the endothelial injury is due to the action
of a constant high level of CsA ampliﬁed by EVE-mediated
inhibition of endothelial cell regeneration. In other words,
endothelial damage caused by CsA does not heal under the
effect of mTORi. A similar interaction should also be
assumed for the association of EVE-FK, but the low num-
ber of such cases in our study does not allow us to draw
conclusions.
EVE-based IS therapy is an important prevention strat-
egy of chronic drug-induced renal toxicity, allowing
minimization of CNI doses. However, as well as SIR, EVE
therapy seems to play a predisposition role in the onset of
de novo TMA. A speciﬁc nephrotoxicity of mTORi has
not been documented to be present on undamaged
2268 NAVA, CAPPELLI, MORI ET ALendothelium. As reported in the literature for SIR, EVE
may be a causal factor in kidneys suffering from ischemic
damage, such as double transplant, or marginal donors [5].
In this study, 2 cases ﬁt this category: 1 double transplant
and 1 extended-criteria donor.
Our study is limited by its retrospective design and the
low number of cases. However, our results are strengthened
by the use of a novel cognitive tool, represented by the
combined monitoring of 2 drugs.
In conclusion, according to our data, TMA is a rare
condition in the setting of renal transplant compared with
the ﬁeld of lung transplantation. Maintaining lower drug
exposure could be the explanation for the different
outcome. In fact, CsA TLC as reported by the German
group (200e250 ng/mL) corresponds to 1000 ng/mL of C
(concentration)max and therefore means no minimization of
CNI. On the contrary, in our minimization protocol, CsA
Cmax (C2) is maintained at w300 to 350 ng/mL. We also
postulate a sequence of endothelial damage by CNI, on
which EVE ﬁts hindering the repair of endothelial injury.
High blood levels of CNI and mTORi seem to predispose
patients to posttransplant TMA. Combined monitoring of
these 2 drugs might be useful for preventing this compli-
cation. Summated blood levels of [everolimus TLC þ (C2/
100)] greater than 12.5 ng/mL should be avoided.
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